Holen Sie sich die Stockscreener-App
4.00
3.90%
0.15
Handel nachbörslich:
4.03
0.03
+0.75%
Schlusskurs vom Vortag:
$3.85
Offen:
$3.87
24-Stunden-Volumen:
3.31M
Relative Volume:
0.75
Marktkapitalisierung:
$1.46B
Einnahmen:
$4.09M
Nettoeinkommen (Verlust:
$-660.15M
KGV:
-1.7351
EPS:
-2.3053
Netto-Cashflow:
$-117.10M
1W Leistung:
+6.38%
1M Leistung:
+8.40%
6M Leistung:
-32.89%
1J Leistung:
+187.77%
1-Tages-Spanne:
$3.86
$4.00
1-Wochen-Bereich:
$3.565
$4.00
52-Wochen-Spanne:
$1.29
$6.75
Ataibeckley Inc Stock (ATAI) Company Profile
Firmenname
Ataibeckley Inc
Sektor
Branche
Telefon
1 929 207 2670
Adresse
C/O ATAI LIFE SCIENCES US, INC., NEW YORK
Compare ATAI vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ATAI
Ataibeckley Inc
|
4.00 | 1.40B | 4.09M | -660.15M | -117.10M | -2.3053 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Ataibeckley Inc Stock (ATAI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-27 | Eingeleitet | Deutsche Bank | Buy |
| 2026-01-20 | Eingeleitet | Guggenheim | Buy |
| 2025-10-13 | Eingeleitet | Needham | Buy |
| 2025-07-29 | Eingeleitet | Oppenheimer | Outperform |
| 2024-11-18 | Bestätigt | H.C. Wainwright | Buy |
| 2024-04-03 | Hochstufung | Maxim Group | Hold → Buy |
| 2022-11-01 | Eingeleitet | Loop Capital | Buy |
| 2021-11-30 | Eingeleitet | Maxim Group | Buy |
| 2021-11-11 | Eingeleitet | ROTH Capital | Buy |
| 2021-10-18 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-09-01 | Eingeleitet | Jefferies | Buy |
| 2021-07-13 | Eingeleitet | Berenberg | Buy |
| 2021-07-13 | Eingeleitet | Canaccord Genuity | Buy |
| 2021-07-13 | Eingeleitet | Cantor Fitzgerald | Buy |
| 2021-07-13 | Eingeleitet | Citigroup | Buy |
| 2021-07-13 | Eingeleitet | Cowen | Outperform |
| 2021-07-13 | Eingeleitet | Credit Suisse | Outperform |
| 2021-07-13 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2021-07-08 | Eingeleitet | Aegis Capital | Buy |
Alle ansehen
Ataibeckley Inc Aktie (ATAI) Neueste Nachrichten
AtaiBeckley (ATAI) Reports Phase 2a Data in CNS Drugs - MSN
HC Wainwright bullish on AtaiBeckley (ATAI) - MSN
Johnson & Johnson’s Spravato sales growth signals upside for psychedelics peers - Proactive financial news
AtaiBeckley to Participate in Upcoming Needham Healthcare Conferences - National Today
AtaiBeckley to Participate in Upcoming Needham Healthcare Conferences - GlobeNewswire Inc.
Positive Phase 2a TRD Data For BPL-003 Might Change The Case For Investing In AtaiBeckley (ATAI) - simplywall.st
5 Stocks Under $5 That Will Explode - insidermonkey.com
AtaiBeckley (HAM:9VC) Cyclically Adjusted Price-to-FCF : (As of Apr. 11, 2026) - GuruFocus
Psychedelic: AtaiBeckley reports publication of BPL-003 study results - TipRanks
Analysts Are Bullish on These Healthcare Stocks: Atai Beckley N.V. (ATAI), MapLight Therapeutics, Inc. (MPLT) - The Globe and Mail
AtaiBeckley Depression Drug Delivers Rapid Day-2 Antidepressant Response - Sahm
Ataibeckley depression drug delivers rapid day-2 antidepressant response - MSN
AtaiBeckley: 'Buy' On New Key Developments For BPL-003 For TRD (NASDAQ:ATAI) - Seeking Alpha
Small cap wrap: AtaiBeckley, EDM Resources, Genflow Biosciences… - Proactive financial news
AtaiBeckley reports rapid response in Phase 2a trial of depression drug BPL-003 - Yahoo! Finance Canada
AtaiBeckley's BPL-003 Shows Rapid, Durable Antidepressant Response in Treatment-Resistant Depression Patients on SSRIs; Phase 2a Data Published in CNS Drugs - Investing News Network
AtaiBeckley's BPL-003 May Lay the Foundation for a Scalable Mental Health System—The Outcome of 2026 Phase 3 Studies Will Determine Its Future - Bitget
AtaiBeckley reports positive phase 2a data for depression drug - Investing.com
AtaiBeckley Announces Positive Phase 2a Results for BPL-003 in Treatment-Resistant Depression with FDA Breakthrough Therapy Designation - Quiver Quantitative
AtaiBeckley’s BPL-003 Shows Rapid, Durable Antidepressant Response in Treatment-Resistant Depression Patients on SSRIs; Phase 2a Data Published in CNS Drugs - The Manila Times
AtaiBeckley reports positive phase 2a data for depression drug By Investing.com - Investing.com UK
AtaiBeckley (ATAI) Valuation Check After Earnings Beat And Mental Health Pipeline Progress - simplywall.st
Deutsche Bank confident of AtaiBeckley Inc. (ATAI) growth prospects on psychedelic medicines - MSN
Deutsche Bank Confident of AtaiBeckley Inc. (ATAI) Growth Prospects on Psychedelic Medicines - Insider Monkey
AtaiBeckley Inc. (ATAI) latest stock news and headlines - Yahoo Finance Singapore
Why AtaiBeckley (ATAI) Is Up 13.1% After Deutsche Bank Highlights Its Post-Merger Pipeline Potential - simplywall.st
AtaiBeckley Inc. (B72.DE) - Yahoo! Finance Canada
ATAI Stock Price, Quote & Chart | ATAIBECKLEY INC (NASDAQ:ATAI) - ChartMill
Deutsche Bank initiates bullish coverage of psychedelics company AtaiBeckley - Mugglehead Investment Magazine
AtaiBeckley Is Said to Explore Options for Main Psychedelic Drug - MSN
AtaiBeckley Inc (ATAI) Stock Price Quote Today & Current Price Chart - Capital.com
Over-the-top psychedelic promos could undermine the field’s drug development efforts - statnews.com
AtaiBeckley Inc (ATAI) Stock Price Quote Today & Current Price Chart | Capital.com Australia - Capital.com
Is Ataibeckley Inc (ATAI) looking to sell its flagship psychedelic drug candidate BPL-003? - MSN
ATAI Technical Analysis | Trend, Signals & Chart Patterns | ATAIBECKLEY INC (NASDAQ:ATAI) - ChartMill
Is It Time To Reassess AtaiBeckley (ATAI) After Its Recent Share Price Slide? - simplywall.st
AtaiBeckley Weighs BPL-003 Deal After Strong Phase 2a And FDA Support - Yahoo Finance
Is Psychedelic Nasal Spray Data And Index Inclusion Altering The Investment Case For AtaiBeckley (ATAI)? - simplywall.st
Deutsche Bank initiates coverage of AtaiBeckley (ATAI) with buy recommendation - MSN
AtaiBeckley Inc. Trade Ideas — TRADEGATE:B72 - TradingView
AtaiBeckley awarded ‘Buy’ rating in initial coverage from Deutsche Bank analysts - Yahoo! Finance Canada
AtaiBeckley initiated with a Buy at Deutsche Bank - TipRanks
Deutsche Bank Initiates AtaiBeckley at Buy With $12 Price Target - MarketScreener
Deutsche Bank initiates Atai Life Sciences stock at buy on psychedelic therapy potential - Investing.com India
Deutsche Bank Initiates AtaiBeckley(ATAI.US) With Buy Rating, Announces Target Price $12 - Moomoo
Deutsche Bank initiates Atai Life Sciences stock at buy on psychedelic therapy potential By Investing.com - Investing.com South Africa
AtaiBeckley sees promising mid-stage results for psychedelic antidepressant - MSN
Finanzdaten der Ataibeckley Inc-Aktie (ATAI)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.69%
0.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):